Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-1-naphthyl-2-acetamido-ethane boronic acid is a small molecule classified as a pharmaceutical. As a boronic acid derivative, it is characterized by its ability to form reversible covalent bonds with various biological molecules. Boronic acids typically interact with 1,2- and 1,3-diols, which are present in saccharides and catechols, and can also bind to nucleophilic amino acid side chains such as serine, histidine, and lysine. This chemical property allows boronic acids to act as enzyme inhibitors by binding to active sites. While the specific therapeutic target and primary indication for D-1-naphthyl-2-acetamido-ethane boronic acid are not explicitly detailed in available public databases, its chemical structure suggests potential for diverse biological activities through these general boronic acid-mediated interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on D-1-naphthyl-2-acetamido-ethane boronic acid.